Topic

Rita Peters is editorial director of Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Articles

Misleading messages contribute to eroding trust in public health agencies.

Fighting the (Dis)Information Pandemic

Editor of Pharmaceutical Technology Europe

European pharma companies may have a vested interest in the outcome of the US elections.

The Elephant (or Donkey) in the Room

AstraZeneca has potentially taken poll position in the race to develop a novel coronavirus vaccine, but will AZD1222 be ready in 2020?

Leader of the Pack?

Amid high expectations for a vaccine, bio/pharma readies capacity, weighs pressures.

Biopharma Gears Up Pandemic Response

Time sure flies, except when you are waiting for something to happen. 

It’s Time to Listen to Science

COVID-19’s impact on the global economy is dealing a blow to merger and acquisition activity in the biopharma industry.

Dealing a Blow to Biopharma

FDA Commissioner Hahn commits to a science-based review and approval process.

Navigating Uncharted Waters

As the coronavirus pandemic unfolds, Pharma must practice science over hype.

Pharma’s Leadership Role in a Pandemic

As COVID-19 rapidly spreads, the bio/pharma industry is committing significant efforts to fast track development of therapies.

Making Every Effort

Despite increasing R&D budgets by bio/pharma companies, returns on this investment are reducing and the cost of bringing an asset to market is increasing.

From the Editor